Cargando…
Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications
Alterations in protein-protein and DNA-protein interactions and abnormal chromatin remodeling are a major cause of uncontrolled gene transcription and constitutive activation of critical signaling pathways in cancer cells. Multiple epigenetic regulators are known to be deregulated in several hematol...
Autores principales: | Reyes-Garau, Diana, Ribeiro, Marcelo L., Roué, Gaël |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826405/ https://www.ncbi.nlm.nih.gov/pubmed/31581671 http://dx.doi.org/10.3390/cancers11101483 |
Ejemplares similares
-
Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma
por: Recasens-Zorzo, Clara, et al.
Publicado: (2019) -
Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma
por: Ribeiro, Marcelo L., et al.
Publicado: (2019) -
Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains
por: Lambert, Jean-Philippe, et al.
Publicado: (2019) -
The BET bromodomain inhibitor ZEN-3365 targets the Hedgehog signaling pathway in acute myeloid leukemia
por: Wellbrock, Jasmin, et al.
Publicado: (2021) -
BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
por: Zhong, Mengjun, et al.
Publicado: (2022)